{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:31:43.804Z","profile":{"slug":"abaloparatide","name":"Abaloparatide","aliases":[],"category":"PTHrP analog"},"synthesis":{"mechanism":"Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.","evidence":"The governed corpus includes the pivotal ACTIVE randomized phase 3 trial, histomorphometry and fracture analyses, the ACTIVExtend antiresorptive-sequencing study, trials in men and Japanese populations, a transdermal formulation trial, real-world comparative research, systematic reviews and network meta-analyses, and mechanistic or preclinical work. Source identities, titles, authorship, publication metadata, DOI/PMID links, peptide identity, and duplication were checked against PubMed. Evidence lanes and strength grades are provisional and preserve study-design boundaries; detailed claim-level risk-of-bias, applicability, and contradiction review remains part of accountable Owner review.","safety":"Most fracture-outcome evidence comes from selected trial populations, especially postmenopausal women, and may not generalize to every patient with osteoporosis. Some studies use bone-mineral density or bone-turnover markers rather than fracture endpoints; indirect comparisons cannot replace adequately powered head-to-head trials. Sponsorship, formulation differences, adherence, background calcium or vitamin D, subsequent antiresorptive therapy, renal function, baseline fracture risk, and jurisdictional labeling affect interpretation. Long-duration human data are limited; rare risks and postmarketing events cannot be fully characterized by preauthorization trials. Current product labeling—not this profile—controls contraindications, warnings, duration, and clinical use.","observationalBoundary":"Across the randomized evidence, daily subcutaneous abaloparatide increased bone-mineral-density measures and reduced new vertebral fractures in postmenopausal women compared with placebo; follow-on alendronate research indicates that antiresorptive treatment can help maintain gains after an anabolic course. Evidence in men supports increased bone density, but fracture-outcome evidence is less mature than in postmenopausal women. Comparative and network-meta-analytic findings help place abaloparatide among anabolic osteoporosis therapies but inherit heterogeneity and indirect-comparison limitations. The archive separately labels human interventional, observational, systematic-review/meta-analysis, mechanistic, and preclinical evidence and does not treat mechanism or animal findings as clinical outcomes.","openQuestions":"Which treatment sequences best preserve fracture protection after abaloparatide? How does it compare directly with teriparatide, romosozumab, and other anabolic strategies for fracture, safety, adherence, quality of life, and cost? What are the long-term cardiovascular, osteosarcoma, hypersensitivity, calcium-metabolism, renal, and postmarketing safety signals? Which men, very old adults, people with chronic kidney disease, and underrepresented populations benefit, and where are fracture rather than surrogate outcomes available? Can alternative delivery systems reproduce the benefit-risk profile of the authorised subcutaneous product? How should real-world persistence and access influence effectiveness?"},"completion":{"version":"wpf-profile-v1.0","complete":false,"checks":[{"key":"overview","passed":true,"actual":684,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":697,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":780,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":813,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":712,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["reviewed_sources","claims"]},"chemistry":{"id":"34a1de5f021bcf7875c26c87d76e1fd4","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","molecularFormula":"C174H300N56O49","molecularWeight":3961,"aminoAcidSequence":"AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA-NH2","smiles":null,"inchi":null,"inchikey":"BVISQZFBLRSESR-XSCWXTNMSA-N","structureImageUrl":"https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/76943386/PNG","createdAt":"2026-09-09T20:32:14.509Z","updatedAt":"2026-09-09T20:32:14.509Z"},"evidence":[{"id":"a9b598989add848c0e580375d034e9c1","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39791502/","evidenceTier":"phase_3","summary":"Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-mo BMD increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men.","authors":"Richard Eastell, Jacques P Brown, Robert A Adler, E Michael Lewiecki, Neil Binkley, Eric S Orwoll, David Kendler, Bruce H Mitlak, Yamei Wang","publishingOrg":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","publicationYear":2025,"doi":"10.1093/jbmr/zjaf003","pubmedId":"39791502","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1093/jbmr/zjaf003","sourceIdentityId":"bcb61c816205300c2f72a419fa118093","sourceStatus":"active","sourceContentHash":"78f4de3822f5e7a0da370883c384faa362635c457eb6c89c3e524b2fb0ed028a","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:39791502","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"A","score":90,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":90,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1093/jbmr/zjaf003","locator":"https://pubmed.ncbi.nlm.nih.gov/39791502/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"78f4de3822f5e7a0da370883c384faa362635c457eb6c89c3e524b2fb0ed028a","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"39791502","rawPayloadReference":"pubmed:39791502"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"66ec3737fea99f37dcf1f57160740939","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39551187/","evidenceTier":"observational","summary":"Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture.","authors":"Laila Tabatabai, Felicia Cosman, Jeffrey R Curtis, Kristi T DeSapri, Clayton T LaBaume, Jean-Yves Reginster, René Rizzoli, Bernard Cortet, Yamei Wang, Joseph Chiodo, Bruce H Mitlak","publishingOrg":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","publicationYear":2025,"doi":"10.1016/j.eprac.2024.10.017","pubmedId":"39551187","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.eprac.2024.10.017","sourceIdentityId":"891103bcdbb0a4971be5b7641c6a9b6a","sourceStatus":"active","sourceContentHash":"0ecc4b71c8687f94f71d8e262754d105cf1b2d418b1775d8bc758011909a54b9","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:39551187","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational comparative study","sourceStrength":{"grade":"B","score":76,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":76,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.eprac.2024.10.017","locator":"https://pubmed.ncbi.nlm.nih.gov/39551187/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"0ecc4b71c8687f94f71d8e262754d105cf1b2d418b1775d8bc758011909a54b9","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"39551187","rawPayloadReference":"pubmed:39551187"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"73f6d9465154801f7a2d596780aa63cd","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40047881/","evidenceTier":"observational","summary":"Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations.","authors":"Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli","publishingOrg":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","publicationYear":2025,"doi":"10.1007/s00198-025-07440-1","pubmedId":"40047881","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00198-025-07440-1","sourceIdentityId":"16e9a58522d8317c0b7bdc90ffc4a7e9","sourceStatus":"active","sourceContentHash":"7ececf23ad88d8f74e88f33117a9c8449e3945111225cbfb6b05be403e4f3518","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:40047881","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review/meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":65,"replication":65,"studyDesign":88,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00198-025-07440-1","locator":"https://pubmed.ncbi.nlm.nih.gov/40047881/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"7ececf23ad88d8f74e88f33117a9c8449e3945111225cbfb6b05be403e4f3518","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"40047881","rawPayloadReference":"pubmed:40047881"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"46fff040fcaf67c790169e32ea6c3c5f","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40214193/","evidenceTier":"phase_1_2","summary":"The goal of treatment for women at high risk of fracture who have a T-score ≤-2.5 is to mitigate fracture risk by achieving T-scores at least above -2.5.","authors":"Felicia Cosman, Bruce H Mitlak, Yamei Wang, Leny Pearman, Carolina A Moreira, E Michael Lewiecki, Steven R Cummings","publishingOrg":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","publicationYear":2025,"doi":"10.1093/jbmr/zjaf053","pubmedId":"40214193","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1093/jbmr/zjaf053","sourceIdentityId":"e77943219bfb678105e90d92d51d5070","sourceStatus":"active","sourceContentHash":"8d0b70753dbb95a95cdfd0347854b95c48f20ae759cace3a0b014b4a74eb1336","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:40214193","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":80,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1093/jbmr/zjaf053","locator":"https://pubmed.ncbi.nlm.nih.gov/40214193/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"8d0b70753dbb95a95cdfd0347854b95c48f20ae759cace3a0b014b4a74eb1336","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"40214193","rawPayloadReference":"pubmed:40214193"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"a0e15a082ffe01615d6c4221e7a3609a","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38691582/","evidenceTier":"phase_3","summary":"Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications.","authors":"Neil P Sheth, James Russell Smith, Renaud Winzenrieth, Ludovic Humbert, Yamei Wang, John I Boxberger, Mathias P Bostrom","publishingOrg":"The Journal of bone and joint surgery. American volume","publicationYear":2024,"doi":"10.2106/jbjs.23.01334","pubmedId":"38691582","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2106/jbjs.23.01334","sourceIdentityId":"c70662effdd8673361fea464481df485","sourceStatus":"active","sourceContentHash":"03a35fccc8e01405818e202fe7eff2abacd961cce4163692a8d79a04fc8ade4f","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:38691582","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"A","score":90,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":90,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.2106/JBJS.23.01334","locator":"https://pubmed.ncbi.nlm.nih.gov/38691582/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"03a35fccc8e01405818e202fe7eff2abacd961cce4163692a8d79a04fc8ade4f","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"38691582","rawPayloadReference":"pubmed:38691582"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"dce631a1add3c24a4ab48626e44b5c94","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38307725/","evidenceTier":"observational","summary":"The aging of the population increases the incidence of postmenopausal osteoporosis, which threatens the health of elderly women.","authors":"Fuxin Xu, Yurun Wang, Xinjian Zhu","publishingOrg":"Clinical therapeutics","publicationYear":2024,"doi":"10.1016/j.clinthera.2023.12.010","pubmedId":"38307725","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.clinthera.2023.12.010","sourceIdentityId":"04e3f5c861ac7b53f00642dabcf310b9","sourceStatus":"active","sourceContentHash":"15902172474b4108add5dc9d15a5ed8f787b1ebbf1fc3a276d6f39874d067de3","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:38307725","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review/meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":88,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.clinthera.2023.12.010","locator":"https://pubmed.ncbi.nlm.nih.gov/38307725/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"15902172474b4108add5dc9d15a5ed8f787b1ebbf1fc3a276d6f39874d067de3","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"38307725","rawPayloadReference":"pubmed:38307725"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"bff8ba1a1be5812f9773dc1017333b4a","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37505256/","evidenceTier":"phase_1_2","summary":"This study aimed to determine the efficacy of abaloparatide in increasing bone mineral density (BMD) and its safety in postmenopausal Japanese women with osteoporosis.","authors":"Toshio Matsumoto, Teruki Sone, Akiko Yamashita, Tetsuo Inoue","publishingOrg":"Journal of bone and mineral metabolism","publicationYear":2023,"doi":"10.1007/s00774-023-01455-6","pubmedId":"37505256","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00774-023-01455-6","sourceIdentityId":"41299929840265b289d692d5c853774b","sourceStatus":"active","sourceContentHash":"a46576fb7142782e25f9b0f837b5f1efe16a25d24fc1ef8c64117937d812e9e4","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:37505256","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":80,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s00774-023-01455-6","locator":"https://pubmed.ncbi.nlm.nih.gov/37505256/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"a46576fb7142782e25f9b0f837b5f1efe16a25d24fc1ef8c64117937d812e9e4","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"37505256","rawPayloadReference":"pubmed:37505256"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"37424f5504ef5561978aa7df43271e86","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36592455/","evidenceTier":"observational","summary":"The prevalence of osteoporosis is increasing in the United States.","authors":"Chelsea Ayers, Devan Kansagara, Brittany Lazur, Rongwei Fu, Amy Kwon, Curtis Harrod","publishingOrg":"Annals of internal medicine","publicationYear":2023,"doi":"10.7326/m22-0684","pubmedId":"36592455","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.7326/m22-0684","sourceIdentityId":"366f2969cd651458814c18fd82d8343b","sourceStatus":"active","sourceContentHash":"30c999e08891458cbf6437935ba7fe26b1b94889aade2e1234cae3d5089418a1","sourceVersion":1,"retrievedAt":"2026-09-10T09:03:43.864Z","retrievalProvider":"pubmed","retrievalPayloadRef":"pubmed:36592455","evidenceLane":null,"extractionPayload":null,"provenancePayload":{"locator":"https://pubmed.ncbi.nlm.nih.gov/36592455/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-10T09:03:43.864Z","rawPayloadHash":"30c999e08891458cbf6437935ba7fe26b1b94889aade2e1234cae3d5089418a1","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36592455","rawPayloadReference":"pubmed:36592455"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":false,"required":true,"reasonCodes":["extraction_not_grounded_or_verified"]},{"id":"G5","passed":false,"required":true,"reasonCodes":["evidence_lane_unresolved"]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"quarantine","reasonCodes":["extraction_not_grounded_or_verified","evidence_lane_unresolved"],"catastrophic":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","roleDemotedFromPromotion":[],"admitsExactPublishedEvidence":true},"engineState":"quarantined","engineRunId":"be21bd35-91c5-43ed-8852-6e31f85ded4c","createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-10T09:04:19.824Z"},{"id":"ffe13684e9372964107cc985ff0a2ebb","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37417725/","evidenceTier":"phase_1_2","summary":"Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC).","authors":"E Michael Lewiecki, Edward Czerwinski, Chris Recknor, Anna Strzelecka, Guillermo Valenzuela, Mary Lawrence, Stuart Silverman, Jose Cardona, Susan M Nattrass, Neil Binkley, Miriam Annett, Leny Pearman","publishingOrg":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","publicationYear":2023,"doi":"10.1002/jbmr.4877","pubmedId":"37417725","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/jbmr.4877","sourceIdentityId":"bc29b71826bcf51cc55572ed4e428273","sourceStatus":"active","sourceContentHash":"d1b9f45df974bdf9c3903463ad84b822709fc0632de3950f7debfeb7fce2524a","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:37417725","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":80,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1002/jbmr.4877","locator":"https://pubmed.ncbi.nlm.nih.gov/37417725/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"d1b9f45df974bdf9c3903463ad84b822709fc0632de3950f7debfeb7fce2524a","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"37417725","rawPayloadReference":"pubmed:37417725"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"af5e209a9318240c7345bb768a62ee33","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36372197/","evidenceTier":"observational","summary":"Osteoporosis medications have been reported to have beneficial and harmful cardiovascular effects.","authors":"Alexander H Seeto, Mina Tadrous, Abadi K Gebre, Joshua R Lewis, Howard A Fink, Peter R Ebeling, Alexander J Rodríguez","publishingOrg":"Bone","publicationYear":2023,"doi":"10.1016/j.bone.2022.116610","pubmedId":"36372197","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.bone.2022.116610","sourceIdentityId":"78cd94fc86f03188d0c3271afd748377","sourceStatus":"active","sourceContentHash":"2c4a9a2d64ab38e9943f8b96b6f15d2baa314c6ba68f9cf618ff0df5f9c5df86","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:36372197","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review/meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":65,"replication":65,"studyDesign":88,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.bone.2022.116610","locator":"https://pubmed.ncbi.nlm.nih.gov/36372197/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"2c4a9a2d64ab38e9943f8b96b6f15d2baa314c6ba68f9cf618ff0df5f9c5df86","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36372197","rawPayloadReference":"pubmed:36372197"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"6b3269d49015302276b7e0e58df0e594","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37130601/","evidenceTier":"observational","summary":"To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors.","authors":"Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid","publishingOrg":"BMJ (Clinical research ed.)","publicationYear":2023,"doi":"10.1136/bmj-2021-068033","pubmedId":"37130601","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1136/bmj-2021-068033","sourceIdentityId":"dc45e85f7fae793b8b628f1cd61abd39","sourceStatus":"active","sourceContentHash":"4b170b609e27503d9693a425eb9a56256c1466e9e6f25c51b6b7562ff673606b","sourceVersion":1,"retrievedAt":"2026-09-10T09:03:43.864Z","retrievalProvider":"pubmed","retrievalPayloadRef":"pubmed:37130601","evidenceLane":null,"extractionPayload":null,"provenancePayload":{"locator":"https://pubmed.ncbi.nlm.nih.gov/37130601/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-10T09:03:43.864Z","rawPayloadHash":"4b170b609e27503d9693a425eb9a56256c1466e9e6f25c51b6b7562ff673606b","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"37130601","rawPayloadReference":"pubmed:37130601"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":false,"required":true,"reasonCodes":["extraction_not_grounded_or_verified"]},{"id":"G5","passed":false,"required":true,"reasonCodes":["evidence_lane_unresolved"]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"quarantine","reasonCodes":["extraction_not_grounded_or_verified","evidence_lane_unresolved"],"catastrophic":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","roleDemotedFromPromotion":[],"admitsExactPublishedEvidence":true},"engineState":"quarantined","engineRunId":"be21bd35-91c5-43ed-8852-6e31f85ded4c","createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-10T09:04:02.368Z"},{"id":"95c504c95055ba1d3883584cbf83f516","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38030806/","evidenceTier":"phase_3","summary":"Daily subcutaneous injection of 80 μg abaloparatide increased bone mineral density in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial.","authors":"Teruki Sone, Kazuhiro Ohnaru, Takumi Sugai, Akiko Yamashita, Nobukazu Okimoto, Tetsuo Inoue, Toshio Matsumoto","publishingOrg":"Archives of osteoporosis","publicationYear":2023,"doi":"10.1007/s11657-023-01344-5","pubmedId":"38030806","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s11657-023-01344-5","sourceIdentityId":"67f94ff4da7c574a49a04a3d9ca878b6","sourceStatus":"active","sourceContentHash":"b2f3798fbcfc2a108e37611445b085871f384a6595fdef96a1c97ff585e1e5b3","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:38030806","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"A","score":90,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":90,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s11657-023-01344-5","locator":"https://pubmed.ncbi.nlm.nih.gov/38030806/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"b2f3798fbcfc2a108e37611445b085871f384a6595fdef96a1c97ff585e1e5b3","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"38030806","rawPayloadReference":"pubmed:38030806"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"d586d82a489e43d63497c590e844fdf8","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36190391/","evidenceTier":"phase_1_2","summary":"Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo.","authors":"Edward Czerwinski, Jose Cardona, Rafal Plebanski, Chris Recknor, Tamara Vokes, Kenneth G Saag, Neil Binkley, E Michael Lewiecki, Jonathan Adachi, Dorota Knychas, David Kendler, Eric Orwoll","publishingOrg":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","publicationYear":2022,"doi":"10.1002/jbmr.4719","pubmedId":"36190391","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/jbmr.4719","sourceIdentityId":"0f4b80a67881caeadc65c38db8389c2b","sourceStatus":"active","sourceContentHash":"4a13f8947008fb03c2bb073e5ec96dc2cd48f6a9d0fb3d2eb61ef8b6407408a1","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:36190391","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":80,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1002/jbmr.4719","locator":"https://pubmed.ncbi.nlm.nih.gov/36190391/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"4a13f8947008fb03c2bb073e5ec96dc2cd48f6a9d0fb3d2eb61ef8b6407408a1","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"36190391","rawPayloadReference":"pubmed:36190391"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"27778e803c16a07eb0a9b9a2ecd132e7","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Abaloparatide: A review of preclinical and clinical studies.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34364879/","evidenceTier":"observational","summary":"Osteoporosis is a debilitating disease characterized by reduced bone mineral density and an increased risk of fractures.","authors":"Mikkel Bo Brent","publishingOrg":"European journal of pharmacology","publicationYear":2021,"doi":"10.1016/j.ejphar.2021.174409","pubmedId":"34364879","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.ejphar.2021.174409","sourceIdentityId":"565ce8d81e1b14103e96ca7c2bb8d9c1","sourceStatus":"active","sourceContentHash":"fa71bd788c900b118022d616ed09cb674581766724d5f2fc59da64078c58b8c9","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:34364879","evidenceLane":"mechanistic","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"peer-reviewed review/mechanistic synthesis","sourceStrength":{"grade":"B","score":70,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":70,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.ejphar.2021.174409","locator":"https://pubmed.ncbi.nlm.nih.gov/34364879/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"fa71bd788c900b118022d616ed09cb674581766724d5f2fc59da64078c58b8c9","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"34364879","rawPayloadReference":"pubmed:34364879"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"d38060d50e0d614856b714c2c589dd4d","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/31674644/","evidenceTier":"phase_3","summary":"The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis.","authors":"Benjamin Z Leder, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, Richard S Bockman","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2020,"doi":"10.1210/clinem/dgz162","pubmedId":"31674644","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/clinem/dgz162","sourceIdentityId":"38e118e1052b1471ed474064cca5e32f","sourceStatus":"active","sourceContentHash":"68071b5487c39258e55ed838b5de984048422ea9f0842c917e13d35ff1bf9166","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:31674644","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"A","score":90,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":90,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/clinem/dgz162","locator":"https://pubmed.ncbi.nlm.nih.gov/31674644/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"68071b5487c39258e55ed838b5de984048422ea9f0842c917e13d35ff1bf9166","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"31674644","rawPayloadReference":"pubmed:31674644"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"a7a08327b6b86665f8d380f00ff4fd41","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/31136739/","evidenceTier":"observational","summary":"Abaloparatide is an analog of human parathyroid hormone-related protein (PTHrP) that has recently been approved for the treatment of post-menopausal osteoporosis.","authors":"Sharmistha Bhattacharyya, Subhashis Pal, Naibedya Chattopadhyay","publishingOrg":"Biochemical pharmacology","publicationYear":2019,"doi":"10.1016/j.bcp.2019.05.024","pubmedId":"31136739","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.bcp.2019.05.024","sourceIdentityId":"640b5fbb36bc62274833f1b51af11d17","sourceStatus":"active","sourceContentHash":"fb66e9f1a7d51570f95a4719ac3d331fed1f0b8109e5dd8f9aa244c665471fd1","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:31136739","evidenceLane":"mechanistic","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"peer-reviewed review/mechanistic synthesis","sourceStrength":{"grade":"C","score":70,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":70,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.bcp.2019.05.024","locator":"https://pubmed.ncbi.nlm.nih.gov/31136739/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"fb66e9f1a7d51570f95a4719ac3d331fed1f0b8109e5dd8f9aa244c665471fd1","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"31136739","rawPayloadReference":"pubmed:31136739"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"22ef5f13f3cb4b3f92aac9115211ccb6","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Abaloparatide: A new pharmacological option for osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/30689744/","evidenceTier":"observational","summary":"The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed.","authors":"Allyson Sleeman, Jennifer N Clements","publishingOrg":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","publicationYear":2019,"doi":"10.1093/ajhp/zxy022","pubmedId":"30689744","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1093/ajhp/zxy022","sourceIdentityId":"11107c705b67cd8f2f69a58d5cb0afdd","sourceStatus":"active","sourceContentHash":"1f991f0013bed839a91530508b0d244af0691f18ba63efdcabe891964d87612f","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:30689744","evidenceLane":"mechanistic","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"peer-reviewed review/mechanistic synthesis","sourceStrength":{"grade":"C","score":70,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":70,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1093/ajhp/zxy022","locator":"https://pubmed.ncbi.nlm.nih.gov/30689744/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"1f991f0013bed839a91530508b0d244af0691f18ba63efdcabe891964d87612f","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"30689744","rawPayloadReference":"pubmed:30689744"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"e80188a8bee6c78287ed4a2cbfbb9977","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/30907957/","evidenceTier":"observational","summary":"Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women.","authors":"Patricia Barrionuevo, Ekta Kapoor, Noor Asi, Fares Alahdab, Khaled Mohammed, Khalid Benkhadra, Jehad Almasri, Wigdan Farah, Maria Sarigianni, Kalpana Muthusamy, Alaa Al Nofal, Qusay Haydour","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2019,"doi":"10.1210/jc.2019-00192","pubmedId":"30907957","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2019-00192","sourceIdentityId":"92cd51fa8b8a44d93865059717a8e8e1","sourceStatus":"active","sourceContentHash":"4435741ae13c7c7125d4a141be0966b97f437c4337e8745ad532e739bc093ff4","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:30907957","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review/meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":65,"replication":65,"studyDesign":88,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2019-00192","locator":"https://pubmed.ncbi.nlm.nih.gov/30907957/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"4435741ae13c7c7125d4a141be0966b97f437c4337e8745ad532e739bc093ff4","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"30907957","rawPayloadReference":"pubmed:30907957"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"c742e43c9a8af23ffea9a8cde6d1e131","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/31066995/","evidenceTier":"laboratory","summary":"Side-effects from allograft, limited bone stock, and site morbidity from autograft are the major challenges to traditional bone defect treatments.","authors":"Ziyu Ning, Baoyu Tan, Bo Chen, Dzi Shing Aaron Lau, Tak Man Wong, Tianhao Sun, Songlin Peng, Zhaoyang Li, William Weijia Lu","publishingOrg":"Macromolecular bioscience","publicationYear":2019,"doi":"10.1002/mabi.201900020","pubmedId":"31066995","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/mabi.201900020","sourceIdentityId":"3e735485d5a579ee8d26263ad699a1fb","sourceStatus":"active","sourceContentHash":"b4a40646afe9076da64d41351039dc7245d73a9a17001e8efe5901d83534d55c","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:31066995","evidenceLane":"preclinical_other","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"preclinical/mechanistic study","sourceStrength":{"grade":"C","score":62,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":62,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1002/mabi.201900020","locator":"https://pubmed.ncbi.nlm.nih.gov/31066995/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"b4a40646afe9076da64d41351039dc7245d73a9a17001e8efe5901d83534d55c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"31066995","rawPayloadReference":"pubmed:31066995"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"452c0521b24b90379626fbc0d00c2508","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/29800372/","evidenceTier":"phase_1_2","summary":"In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO).","authors":"Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli, Robin K Dore, John P Bilezikian","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2018,"doi":"10.1210/jc.2018-00163","pubmedId":"29800372","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2018-00163","sourceIdentityId":"ab158026847a3a6500210e2ff97dcff4","sourceStatus":"active","sourceContentHash":"ffa1dc2893096d94c518915c5b7e5ae81547c47972d3ab0a7c4e937265843d31","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:29800372","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":80,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2018-00163","locator":"https://pubmed.ncbi.nlm.nih.gov/29800372/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"ffa1dc2893096d94c518915c5b7e5ae81547c47972d3ab0a7c4e937265843d31","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"29800372","rawPayloadReference":"pubmed:29800372"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"88a46cd68d5fc93ad33a169a85e71e4c","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/29241341/","evidenceTier":"observational","summary":"To review the efficacy, safety, and economics of abaloparatide in the treatment of postmenopausal osteoporosis.","authors":"Eric G Boyce, Yvonne Mai, Christopher Pham","publishingOrg":"The Annals of pharmacotherapy","publicationYear":2018,"doi":"10.1177/1060028017748649","pubmedId":"29241341","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1177/1060028017748649","sourceIdentityId":"95ce3e6306b6d80c9b88150956099dae","sourceStatus":"active","sourceContentHash":"4202e5f127428180574150507f954489fe5aae28b4ca5e02f53d22638de48584","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:29241341","evidenceLane":"mechanistic","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"peer-reviewed review/mechanistic synthesis","sourceStrength":{"grade":"C","score":70,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":70,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1177/1060028017748649","locator":"https://pubmed.ncbi.nlm.nih.gov/29241341/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"4202e5f127428180574150507f954489fe5aae28b4ca5e02f53d22638de48584","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"29241341","rawPayloadReference":"pubmed:29241341"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"3ce9ef267e52c2cb2ebb4799b29af5b2","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Abaloparatide: First Global Approval.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/28624872/","evidenceTier":"observational","summary":"Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis.","authors":"Matt Shirley","publishingOrg":"Drugs","publicationYear":2017,"doi":"10.1007/s40265-017-0780-7","pubmedId":"28624872","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40265-017-0780-7","sourceIdentityId":"67bc7f90d578a365495dcf4a68ad8bf0","sourceStatus":"active","sourceContentHash":"4ff2cbda9db85582ea4b892cec09a95545b44aa2c5d36f19af85fc679c6fe68c","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:28624872","evidenceLane":"mechanistic","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"peer-reviewed review/mechanistic synthesis","sourceStrength":{"grade":"C","score":65,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":65,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s40265-017-0780-7","locator":"https://pubmed.ncbi.nlm.nih.gov/28624872/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"4ff2cbda9db85582ea4b892cec09a95545b44aa2c5d36f19af85fc679c6fe68c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"28624872","rawPayloadReference":"pubmed:28624872"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"b78ea25941717ed7722bd6740e6a6ab3","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27826127/","evidenceTier":"phase_3","summary":"There are a number of effective treatments for osteoporosis but most are in the antiresorptive class of compounds.","authors":"Carolina A Moreira, Lorraine A Fitzpatrick, Yamei Wang, Robert R Recker","publishingOrg":"Bone","publicationYear":2017,"doi":"10.1016/j.bone.2016.11.004","pubmedId":"27826127","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.bone.2016.11.004","sourceIdentityId":"17018b920d3ecebe17695a9309f94328","sourceStatus":"active","sourceContentHash":"3882a0b71a6fbedb6cc37c92ba2484b7516e7133adad86f12ebc8faf2844037a","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:27826127","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"A","score":90,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":90,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.bone.2016.11.004","locator":"https://pubmed.ncbi.nlm.nih.gov/27826127/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"3882a0b71a6fbedb6cc37c92ba2484b7516e7133adad86f12ebc8faf2844037a","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"27826127","rawPayloadReference":"pubmed:27826127"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"2303a3aba5c6b1b0ab621eb1524a292e","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/28680788/","evidenceTier":"observational","summary":"Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis.","authors":"Sri Harsha Tella, Anuhya Kommalapati, Ricardo Correa","publishingOrg":"Cureus","publicationYear":2017,"doi":"10.7759/cureus.1300","pubmedId":"28680788","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.7759/cureus.1300","sourceIdentityId":"3648c560d173cb157d02c004b28f1b3a","sourceStatus":"active","sourceContentHash":"111a26d6706d889a17a8feb67faeede639a7ad317c98b9910b3a05affb2bd2f0","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:28680788","evidenceLane":"mechanistic","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"peer-reviewed review/mechanistic synthesis","sourceStrength":{"grade":"B","score":70,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":70,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.7759/cureus.1300","locator":"https://pubmed.ncbi.nlm.nih.gov/28680788/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"111a26d6706d889a17a8feb67faeede639a7ad317c98b9910b3a05affb2bd2f0","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"28680788","rawPayloadReference":"pubmed:28680788"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"},{"id":"217cbcfad7e10a0130babf9c108eeeb0","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27533157/","evidenceTier":"phase_3","summary":"Additional therapies are needed for prevention of osteoporotic fractures.","authors":"Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris, Lorraine A Fitzpatrick, Felicia Cosman","publishingOrg":"JAMA","publicationYear":2016,"doi":"10.1001/jama.2016.11136","pubmedId":"27533157","jurisdiction":null,"dateAccessed":"2026-09-09T20:30:37.014Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the abaloparatide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1001/jama.2016.11136","sourceIdentityId":"3978424905dc56d6a8e255a35de4f7e7","sourceStatus":"active","sourceContentHash":"91e810e329e229ded77375640d4f6e119da4bb63c9ea5e76db9150d8862836b6","sourceVersion":1,"retrievedAt":"2026-09-09T20:30:37.014Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:27533157","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized clinical trial","sourceStrength":{"grade":"A","score":90,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":80,"replication":65,"studyDesign":90,"regulatoryRelevance":55},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1001/jama.2016.11136","locator":"https://pubmed.ncbi.nlm.nih.gov/27533157/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T20:20:00Z","rawPayloadHash":"91e810e329e229ded77375640d4f6e119da4bb63c9ea5e76db9150d8862836b6","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"27533157","rawPayloadReference":"pubmed:27533157"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T20:30:37.014Z","updatedAt":"2026-09-09T20:35:44.325Z"}],"regulatory":[{"id":"7594a78f777ff22286be3bbb0e0454cd","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","jurisdiction":"European Union (EMA)","status":"approved","approvedIndication":"ELADYNOS (abaloparatide) is centrally authorised in the European Union for treatment of osteoporosis in postmenopausal women at increased risk of fracture.","rationale":"EU authorization is medicine-, formulation-, population-, and indication-specific. The current Summary of Product Characteristics and package leaflet control; this entry does not extend the authorization to men or to unapproved formulations in the EU.","sourceTitle":"EMA EPAR — Eladynos (EMEA/H/C/005928)","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos","dateChecked":"2026-09-09T20:32:14.509Z","reviewDueAt":"2026-12-08T20:32:14.509Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-09T20:32:14.509Z","updatedAt":"2026-09-09T20:35:44.336Z"},{"id":"a5cba6144bf989ed32e5ebc79a2d057b","peptideId":"79114279-4cc1-4c94-8445-c3157edccb40","jurisdiction":"United States (FDA)","status":"approved","approvedIndication":"TYMLOS (abaloparatide) is FDA-approved for treatment of postmenopausal women with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture or with the same treatment-history criteria.","rationale":"Authorization is specific to TYMLOS, its labeled populations, route, formulation, duration, warnings, and current prescribing information. It does not authorize other formulations or uses.","sourceTitle":"FDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208743s018lbl.pdf","dateChecked":"2026-09-09T20:32:14.509Z","reviewDueAt":"2026-12-08T20:32:14.509Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-09T20:32:14.509Z","updatedAt":"2026-09-09T20:35:44.336Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}